文献速递乳腺外科围术期管理与 ERAS

临床淋巴结阴性乳腺癌新辅助化疗后省略前哨淋巴结活检的探索

Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
PubMed 文献 · Br J Surg · 2021-01-01

该队列研究纳入2013至2018年接受新辅助化疗后行乳腺手术及前哨淋巴结活检的cT1-3 cN0乳腺癌患者303例,其中259例(85.5%)达到ypN0。

要点

  • cN0乳腺癌新辅助化疗后ypN0率为85.5%,腋窝阳性概率总体较低。
  • 三阴性或HER2阳性且MRI影像学完全缓解者腋窝阳性概率低于3%。

核心结论

  • cN0乳腺癌新辅助化疗后ypN0率较高,三阴性或HER2阳性且MRI乳腺影像学完全缓解者腋窝阳性概率低于3%,可纳入省略前哨淋巴结活检的临床试验。

研究设计与样本

  • 回顾性队列研究,纳入2013至2018年接受新辅助化疗后行乳腺手术及前哨淋巴结活检的cT1-3 cN0乳腺癌患者303例。
  • cN0定义为超声及PET/CT未见可疑淋巴结,或细针穿刺未见肿瘤细胞。
  • 采用单因素及多因素logistic回归分析ypN0的预测因素。

主要发现

  • 303例中259例(85.5%)达到ypN0。
  • 激素受体阳性且rCR者82%达到ypN0,三阴性且rCR者98%达到ypN0,HER2阳性且rCR者全部达到ypN0。

关键数值与推荐

  • 总体ypN0率为85.5%(259/303)。
  • 三阴性或HER2阳性且乳腺MRI达rCR者新辅助化疗后腋窝阳性概率低于3%。

临床怎么用

  • 对三阴性或HER2阳性且MRI乳腺达rCR的cN0患者,可考虑在临床试验框架内评估省略前哨淋巴结活检。
  • 目前证据尚不足以在试验外常规省略前哨淋巴结活检。

局限性

  • 为单中心队列研究,样本量303例,结论需前瞻性试验验证。
  • 乳腺rCR与ypN0的关联仅为趋势性,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The nodal positivity rate after neoadjuvant chemotherapy (ypN+) in patients with clinically node-negative (cN0) breast cancer is low, especially in those with a pathological complete response of the breast. The aim of this study was to identify characteristics known before surgery that are associated with achieving ypN0 in patients with cN0 disease. These characteristics could be used to select patients in whom sentinel lymph node biopsy may be omitted after neoadjuvant chemotherapy. METHODS: This cohort study included patients with cT1-3 cN0 breast cancer treated with neoadjuvant chemotherapy followed by breast surgery and sentinel node biopsy between 2013 and 2018. cN0 was defined by the absence of suspicious nodes on ultrasound imaging and PET/CT, or absence of tumour cells at fine-needle aspiration. Univariable and multivariable logistic regression analyses were performed to determine predictors of ypN0. RESULTS: Overall, 259 of 303 patients (85.5 per cent) achieved ypN0, with high rates among those with a radiological complete response (rCR) on breast MRI (95·5 per cent). Some 82 per cent of patients with hormone receptor-positive disease, 98 per cent of those with triple-negative breast cancer (TNBC) and all patients with human epidermal growth factor receptor 2 (HER2)-positive disease who had a rCR achieved ypN0. Multivariable regression analysis showed that HER2-positive (odds ratio (OR) 5·77, 95 per cent c.i. 1·91 to 23·13) and TNBC subtype (OR 11·65, 2·86 to 106·89) were associated with ypN0 status. In addition, there was a trend toward ypN0 in patients with a breast rCR (OR 2·39, 0·95 to 6·77). CONCLUSION: The probability of nodal positivity after neoadjuvant chemotherapy was less than 3 per cent in patients with TNBC or HER2-positive disease who achieved a breast rCR on MRI. These patients could be included in trials investigating the omission of sentinel node biopsy after neoadjuvant chemotherapy.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. van der Noordaa MEM, van Duijnhoven FH, Cuijpers FNE, et al. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer. Br J Surg. 2021. PMID: 34157085. doi:10.1002/bjs.12026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。